Newgenivf Group Limited
Officers & Directors
Wing Fung Alfred Siu, age 71, is Chairman of the Board and Chief Executive Officer of NewGenIvf, positions he has held since co-founding the company in 2019. He previously served as a director of First Fertility PGS Center Co., Ltd. from 2014. He holds a master's and bachelor's degree in science from Stanford University.
Hei Yue Tina Fong, age 44, is a Director and Chief Marketing Officer of NewGenIvf, serving since 2019. She was also a director of First Fertility PGS Center Co., Ltd. from 2014. She holds a bachelor's degree in marketing from Indiana University.
Ho Fai Chung, age 62, has been Chief Financial Officer of NewGenIvf since October 10, 2024. He is a U.S. certified public accountant with over 30 years of experience in Asia. His academic credentials include a Bachelor of Law from University of London, a Master’s in Accounting and Finance from Lancaster University, and a Master’s in International and Public Affairs from Hong Kong University. He began his career at Price Waterhouse in Hong Kong and has worked across various industries in Asia.
Hok Man Jefferson Au, age 45, has served as an Independent Director since April 3, 2024. He is Assistant Financial Controller and Company Secretary at Coolpoint Innonism Holding Limited since 2017 and a director of JWMG CPA Limited since 2014. Previously, he worked as an audit supervisor at Clement C.W. Chan & Co. He holds an honours diploma in accounting from Hong Kong Shue Yan University and a Master of Science in professional accountancy from University of London. He is a member of the Hong Kong Institute of Certified Public Accountants and an associate of the Association of Chartered Certified Accountants.
Florianna Ann Chi Wan Chan, age 45, has been an Independent Director since April 15, 2025. She has over 20 years of experience in project management, real estate development, and luxury hospitality. Since 2015, she has led Lab Concept Company Limited, a subsidiary of The Lane Crawford Joyce Group. She previously held senior roles at VCC Company Limited, Eton Properties, and Crown Macau. She holds a Bachelor of Hospitality Management from Central Queensland University and an Advanced Diploma from William Angliss Institute of TAFE.
Chun Wa Tam, age 62, has served as an Independent Director since November 29, 2024. Since December 2023, he has been CFO, company secretary, and authorised representative of China Asia Valley Group Limited. He has been an independent non-executive director of Green Energy Group Limited since August 24, 2011, and was CFO, company secretary, and authorised representative of Perfect Group International Holdings Limited from February 2017 to November 2023. The shares of these companies are listed on the Main Board of the Stock Exchange.
News about Newgenivf Group Limited Key Personnel |
In the rapidly evolving landscape of reproductive technology and healthcare, NewGen IVF Group Limited (NASDAQ: NIVF) stands at a pivotal juncture. The company finds itself clarifying its recent press release, issuing a critical statement regarding its compliance standing with ...
|
NewGenIvf Strengthens Financial Position with $100 Million Equity Line of Credit amid Nasdaq Compliance ChallengeIn a significant development for NewGenIvf Group Limited (NASDAQ: NIVF), the company has entered into a binding term sheet with White Lion Capital, LLC, which outlines a $100 million equity line of credit with the potential for expansion up to $500 million. This move, announced on November 18, 2024, is aimed at propelling NewGenIvf’s innovative projects within the burgeoning fertility solutions sector, particularly in the Asian market. Financial Backbone for GrowthThis $100 million credit line, facilitated by White Lion Capital—known for investing in high-growth, early-stage public companiesâ€...
|
NewGenIvf Group, a leading fertility services provider in Asia, has recently announced an update on its ongoing evaluation of a potential reverse merger with COVIRIX Medical Pty Ltd. This proposed merger could potentially revolutionize the fertility industry and improve access to cutting-edge treatments. With NewGen s expertise and COVIRIX s advanced medical technologies, this collaboration promises to provide new opportunities for couples and individuals struggling with fertility issues across Asia and beyond.
The Importance of the Proposed Reverse Merger:
The prospect of combining NewGenIvf s established market presence and COVIRIX s innovative medical solutions has generated significant ...
|
NewGenIvf Group Limited, a leading IVF technology company listed on the Nasdaq Stock Market (NASDAQ: NIVF), has recently encountered compliance issues with the Nasdaq Listing Rules. In two letters received on May 24, 2024, the Listing Qualifications Department of The Nasdaq Stock Market LLC notified NewGenIvf that it is currently not in compliance with certain requirements. This development raises concerns about the market value of the company s publicly held shares and listed securities.
Background:
NewGenIvf is an innovative corporation specializing in fertility treatment and reproductive technologies. Its cutting-edge solutions have garnered significant attention and propelled the compan...
|
|
|
